2021;10:e020654
Therefore, semaglutide could improve other obesity-related pathologies like cardiovascular, hypertension, or fatty liver diseases
However, the studys robustness was limited by small group sizes, incomplete statistical data on MapK and TNF-, and contradictory findings regarding gene expression differences (Daneshmand et al., 2016)
Research shows that while 50-60% of users experience gastrointestinal side effects initially, these are usually mild to moderate and transient
Semaglutide has been structurally modified to prevent it from being broken down by an enzyme in the blood called dipeptidyl peptidase-4 or DPP-4
Researchers found that certain bacteria can promote trimethylamine-N-oxide (TMAO), which may cause platelet hyperreactivity and thrombus formation